MHH Logo
Medizinische Hochschule Hannover | Carl-Neuberg-Str.1 | 30625 Hannover | Tel.:(+49) 0511-532-0

Institute of Clinical Biochemistry


Professor Dr. S. Lenzen




Hannover Medical School 

Institute of Clinical Biochemistry

OE 4340

Carl-Neuberg-Str. 1

30625 Hannover, Germany

Tel. : +49 511 532 - 6525

Fax : +49 511 532 - 3584



Scientific staff:



The aim of clinical biochemistry research is to investigate the cellular and molecular basis of diseases. Research is being carried out on a disease model in cooperation with experimental and clinical groups by using biochemical, cell biological, molecular biological, and molecular morphological methods.


The research area of the Institute of Clinical Biochemistry at the MHH is the experimental diabetology, focusing on pancreatic islet biology. The research comprises:

  1. the insulin secretory function of the beta cells of the pancreas and the molecular basis of signal recognition and signalling pathways leading to exocytosis of insulin;
  2. the causes and mechanisms of dysfunction and death of pancreatic beta cells, underlying the insulin dependent (type 1) and insulin independent (type 2) diabetes;
  3. the development of gene, stem cell, immunomodulatory, and new pharmacological therapeutic approaches to treat and prevent diabetes (type 1 & type 2)


Research area: Experimental diabetes research   

Research focuses:

  • Cell and molecular biology of the islets of Langerhans
  • Mechanisms of glucose-induced insulin secretion and signal recognition in pancreatic beta cells
  • Molecular biology of glucose transport (GLUT2 glucose transporter) and glucose phosphorylation (glucokinase) in beta cells and liver
  • Mechanisms of selective beta cell dysfunction and death by necrosis and apoptosis through cytokines (T1DM) and lipotoxicity (T2DM)
  • Importance of cytoprotective enzymes for protection against beta cell death
  • Mechanisms of diabetogenic action of alloxan and streptozotocin
  • Bioengineering of insulin-producing surrogate cells through differentiation of stem cells
  • Mechanisms of action of antihyperglycemic drugs
  • Gene therapy of insulin-dependent diabetes mellitus (IDDM)
  • Type 1 and type 2 diabetes animal models
  • The LEW.1AR1.-iddm rat (IDDM rat) as an animal model of human T1DM and the characterisation of the underlying pathomechanisms of beta cell death in autoimmune diabetes
  • Immunomodulatory therapies for prevention and cure of T1DM


Recent Reviews:

  1. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 51, 216-226, 2008 (Review)
  2. Lenzen S. Oxidative stress: the vulnerable beta cell. Biochem Soc Trans 36, 343-347, 2008 (Review)
  3. Gehrmann W, Elsner M, Lenzen S. Role of metabolically generated reactive oxygen species for lipotoxicity in pancreatic beta cells. Diabetes Obes Metab 12 (Suppl. S2), 149-158, 2010 (Review)
  4. Naujok O, Burns C, Jones PM, Lenzen S. Insulin-producing surrogate beta cells from embryonic stem cells - Are we there yet? Mol Ther 19, 1759-1768, 2011 (Review)

For original publications from the Institute of Clinical Biochemistry at the MHH:

see "PubMed" (link) on the internet under "Lenzen-S"

Blutkonserven sind an der MHH häufig knapp. Warum?


Die Medizinische Hochschule Hannover hat sich zur größten Transplantationsklinik in Deutschland entw...